Showing 1894 results
July 2016
-
Press release
Novartis erzielt im 2. Quartal solide Ergebnisse trotz US-Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige Wachstumsperspektiven
Der Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%… -
Featured News
Beyond the pill: precision medicine in practice
Learn how we are shifting from making the patient fit the treatment to making the treatment fit the patient.
-
Press release
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience… -
Press release
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product … -
Press release
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the… -
In The News
Novartis Access perspectives: Kenya's New Health Care Battle
An opinion piece by Dr. Samuel Mwenda published in US News & World Report -
Featured News
Novartis: evolving business practices to better educate the medical community
Seeking to evolve the way it educates and engages with healthcare professionals, Novartis is using digital technology to enhance the quality, transparency and reach of its interactions with the medical community.
June 2016
-
In The News
Perfecting access through embedded sustainability, pooling resources and consolidating expertise
A guest blog post from Anthony Gitau, Country Head of Novartis Access and Familia Nawiri in Kenya. -
Press release
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[… -
Story From Our Labs
Molecular glue kills cancer cells in mice
Compounds block a protein involved in many cancers by cementing it shut.
-
Press release
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin
Global survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not… -
Press release
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…